These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 10377437)

  • 1. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
    Nussenblatt RB; Fortin E; Schiffman R; Rizzo L; Smith J; Van Veldhuisen P; Sran P; Yaffe A; Goldman CK; Waldmann TA; Whitcup SM
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7462-6. PubMed ID: 10377437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
    Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
    J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
    Sen HN; Levy-Clarke G; Faia LJ; Li Z; Yeh S; Barron KS; Ryan JG; Hammel K; Nussenblatt RB
    Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
    Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
    J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].
    Hernández Garfella ML; Díaz Llopis M; Salom Alonso D; Cervera Taulet E
    Arch Soc Esp Oftalmol; 2004 Dec; 79(12):593-8. PubMed ID: 15627927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
    Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
    Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
    Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy.
    Egwuagu CE; Yu CR; Li Z; Nussenblatt RB
    J Autoimmun; 2005 Feb; 24(1):39-46. PubMed ID: 15725575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.
    Sepah YJ; Sadiq MA; Chu DS; Dacey M; Gallemore R; Dayani P; Hanout M; Hassan M; Afridi R; Agarwal A; Halim MS; Do DV; Nguyen QD
    Am J Ophthalmol; 2017 Nov; 183():71-80. PubMed ID: 28887113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin.
    Nussenblatt RB; de Smet MD; Rubin B; Freidlin V; Whitcup SM; Davis J; Herman D; Bloom JN; Sran PK; Whitcher S
    Am J Ophthalmol; 1993 May; 115(5):583-91. PubMed ID: 8488909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
    Wroblewski K; Sen HN; Yeh S; Faia L; Li Z; Sran P; Gangaputra S; Vitale S; Sherry P; Nussenblatt R
    Can J Ophthalmol; 2011 Aug; 46(4):322-8. PubMed ID: 21816251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs in the treatment of noninfectious uveitis].
    Cano-Parra J; Díaz-Llopis M
    Arch Soc Esp Oftalmol; 2006 Dec; 81(12):671-3. PubMed ID: 17199159
    [No Abstract]   [Full Text] [Related]  

  • 20. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.